UMHAT Dr. Georgi Stranski, EAD
About UMHAT Dr. Georgi Stranski, EAD
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Janssen Research & Development, LLC
8
Pfizer
8
Hoffmann-La Roche
5
Agios Pharmaceuticals, Inc.
2
Bayer
2
H. Lundbeck A/S
2
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2
Takeda
2
AbbVie
1
Advanz Pharma
1
Agennix
1
Clinical Trials at UMHAT Dr. Georgi Stranski, EAD
During the past decade, UMHAT Dr. Georgi Stranski, EAD conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 21 clinical trials were completed, i.e. on
average, 51.2% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 11 clinical trials were completed. i.e. 78.6%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
2007-03-01
2008-07-01
Completed
735
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
2008-11-01
2012-08-01
Completed
742
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
2010-09-01
2016-06-01
Terminated
2,867
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
2010-09-01
2013-01-01
Completed
666
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
2010-11-01
2013-01-01
Completed
1,101
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
2011-07-01
Completed
413
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
2012-02-21
2019-08-22
Completed
605
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
2010-07-07
2020-04-29
Completed
4,501
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "UMHAT Dr. Georgi Stranski, EAD" #1 sponsor was "Janssen Research & Development, LLC" with 8 trials, followed by "Pfizer" with 8 trials
sponsored, "Hoffmann-La Roche" with 5 trials sponsored, "Agios Pharmaceuticals, Inc." with 2 trials sponsored and "Bayer"
with 2 trials sponsored. Other sponsors include 24 different institutions and
companies that sponsored additional 31 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "UMHAT Dr. Georgi Stranski, EAD"
#1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "Gynecologic Oncology Group" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were
collaborators in the rest 12 trials.
Clinical Trials Conditions at UMHAT Dr. Georgi Stranski, EAD
According to Clinical.Site data, the most researched conditions in "UMHAT Dr. Georgi Stranski, EAD" are
"Psoriasis" (5 trials), "Schizophrenia" (4 trials), "Arthritis, Psoriatic" (2 trials), "Atrial Fibrillation" (2 trials) and "Colitis, Ulcerative" (2 trials). Many other conditions were trialed in "UMHAT Dr. Georgi Stranski, EAD" in a lesser frequency.
Clinical Trials Intervention Types at UMHAT Dr. Georgi Stranski, EAD
Most popular intervention types in "UMHAT Dr. Georgi Stranski, EAD" are "Drug" (49 trials), "Biological" (5 trials), "Other" (4 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (17 trials), "CP-690,550" (2 trials), "Cariprazine" (2 trials), "Docetaxel" (2 trials) and "Guselkumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at UMHAT Dr. Georgi Stranski, EAD
The vast majority of trials in "UMHAT Dr. Georgi Stranski, EAD" are
50 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.
Clinical Trials Status at UMHAT Dr. Georgi Stranski, EAD
Currently, there are NaN active trials in "UMHAT Dr. Georgi Stranski, EAD".
undefined are not yet recruiting,
11 are recruiting,
7 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 29 completed trials in UMHAT Dr. Georgi Stranski, EAD,
undefined suspended trials,
and 7 terminated clinical trials to date.
Out of the total trials that were conducted in UMHAT Dr. Georgi Stranski, EAD, 0 "Phase 1"
clinical trials were conducted, 12 "Phase 2" clinical
trials and 34 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 3 trials, and there were
also 1 trials that are defined as “Not Applicable".